|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
25
|
|
pubmed:dateCreated |
2004-6-23
|
|
pubmed:abstractText |
Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between primary tumor and metastases. Therefore, patients with HER-2-negative primary tumors rarely will receive anti-Her-2 antibody (trastuzumab, Herceptin) therapy. A very sensitive blood test was used to capture circulating tumor cells (CTCs) and evaluate their HER-2 gene status by fluorescence in situ hybridization. The HER-2 status of the primary tumor and corresponding CTCs in 31 patients showed 97% agreement, with no false positives. In 10 patients with HER-2-positive tumors, the HER-2/chromosome enumerator probe 17 ratio in each tumor was about twice that of the corresponding CTCs (mean 6.64 +/- 2.72 vs. 2.8 +/- 0.6). Hence, the ratio of the CTCs is a reliable surrogate marker for the expected high ratio in the primary tumor. Her-2 protein expression of 10 CTCs was sufficient to make a definitive diagnosis of the HER-2 gene status of the whole population of CTCs in 19 patients with recurrent breast cancer. Nine of 24 breast cancer patients whose primary tumor was HER-2-negative each acquired HER-2 gene amplification in their CTCs during cancer progression, i.e., 37.5% (95% confidence interval of 18.8-59.4%). Four of the 9 patients were treated with Herceptin-containing therapy. One had a complete response and 2 had a partial response.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-11248153,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-11454672,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-12114406,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-12176781,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-12370762,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-12738987,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-14567724,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-14579298,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-14692077,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-2470152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-3552208,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-6491298,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-7522511,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-7605658,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-8694559,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-9539782,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15194824-9560368
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
pubmed-author:AshfaqRaheelaR,
pubmed-author:BeitschPeterP,
pubmed-author:CliffordEdwardE,
pubmed-author:EuhusDavidD,
pubmed-author:FehmTanjaT,
pubmed-author:FlemingTimothyT,
pubmed-author:FrenkelEugeneE,
pubmed-author:HaleyBarbaraB,
pubmed-author:HerlynDorotheeD,
pubmed-author:HooverSusanS,
pubmed-author:KhanAmanullahA,
pubmed-author:LaneNancyN,
pubmed-author:LeitchMarilynM,
pubmed-author:MengSongdongS,
pubmed-author:MorrisonLarryL,
pubmed-author:OsborneCynthiaC,
pubmed-author:PerkinsSteveS,
pubmed-author:SheteSanjayS,
pubmed-author:TerstappenLeon W M MLW,
pubmed-author:TripathyDebasishD,
pubmed-author:TuckerThomasT,
pubmed-author:UhrJonathanJ,
pubmed-author:VitettaEllenE,
pubmed-author:WangJianqiangJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
22
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
9393-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15194824-Antibodies, Monoclonal,
pubmed-meshheading:15194824-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15194824-Breast Neoplasms,
pubmed-meshheading:15194824-Chromosome Mapping,
pubmed-meshheading:15194824-Disease Progression,
pubmed-meshheading:15194824-Female,
pubmed-meshheading:15194824-Gene Amplification,
pubmed-meshheading:15194824-Genes, erbB-2,
pubmed-meshheading:15194824-Humans,
pubmed-meshheading:15194824-In Situ Hybridization, Fluorescence,
pubmed-meshheading:15194824-Neoplasm Staging,
pubmed-meshheading:15194824-Patient Selection,
pubmed-meshheading:15194824-Predictive Value of Tests,
pubmed-meshheading:15194824-Tumor Markers, Biological
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
HER-2 gene amplification can be acquired as breast cancer progresses.
|
|
pubmed:affiliation |
Cancer Immunobiology Center, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
